Current Value
$0.581 Year Return
Current Value
$0.581 Year Return
Yahoo
Published Before-and-After Photos Highlight Dramatic Improvements in Netherton Syndrome Patient Treated with QRX003NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company’s notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet medical
Yahoo
Highly Positive Clinical Data on Completion of Testing for First Subject Dosed Twice Daily with QRX003 in Open-Label StudyDemonstrated Clinical Benefits from QRX003 Observed Across All Measured EndpointsBefore and After Dosing with QRX003 Photographs Available for Review On WebsiteNo Product Safety Concerns Identified in Any Quoin Netherton Study to Date ASHBURN, Va., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, special
Yahoo
ASHBURN, Va., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its “reasonable best efforts” public offering of 15,111,110 ordinary shares represented by 15,111,110 American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof), Series F warrants to purchase an aggregate of up to 15,111,110 ordinary shares repr
Yahoo
Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface area over a 12-week periodStudy intended to generate data based on product use resembling potential real-world useThird Netherton Syndrome clinical study to be conducted under Quoin’s open Investigational New Drug application ASHBURN, Va., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (N
Yahoo
Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin Appearance Observed in Pediatric Study after Only 12 Days of Dosing with QRX003 ASHBURN, Va., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from two of its o
Yahoo
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations Quoin Pharmaceuticals (NASDAQ:QNRX) provided a business update last week. The company implemented a number of measures during the quarter to move lead asset QRX003 forward. For instance,
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AVAV | -18.88% | $4.66B | +33.67% | 0.00% |
DAVE | -18.68% | $1.14B | +647.45% | 0.00% |
SVC | -17.59% | $424.95M | -68.32% | 23.60% |
PENG | -16.73% | $1.07B | -11.21% | 0.00% |
OFG | -16.62% | $1.99B | +24.50% | 2.29% |
BSM | -16.09% | $3.27B | -3.90% | 10.33% |
MVO | -15.78% | $93.84M | -29.04% | 16.05% |
NNE | -15.16% | $772.61M | +485.25% | 0.00% |
HIHO | -13.97% | $8.43M | -6.13% | 6.27% |
NTZ | -13.45% | $51.00M | -28.58% | 0.00% |
STG | -13.09% | $29.30M | -34.12% | 0.00% |
MTRX | -12.74% | $395.14M | +53.86% | 0.00% |
GTE | -11.67% | $278.56M | +58.18% | 0.00% |
FTI | -11.10% | $13.85B | +70.92% | 0.61% |
FENG | -10.71% | $13.15M | +65.52% | 0.00% |
FMS | -10.66% | $13.59B | +19.50% | 2.78% |
DVA | -10.62% | $13.52B | +56.39% | 0.00% |
MGPI | -10.60% | $788.34M | -59.45% | 1.33% |
AVO | -10.21% | $888.56M | +24.18% | 0.00% |
BIO | -9.77% | $9.64B | +13.27% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CASI | -<0.01% | $33.50M | -50.40% | 0.00% |
RACE | <0.01% | $77.67B | +24.73% | 0.60% |
VIST | <0.01% | $5.55B | +87.80% | 0.00% |
TFSL | <0.01% | $3.52B | -8.54% | 8.99% |
WU | 0.01% | $3.56B | -11.87% | 8.92% |
APO | 0.01% | $93.88B | +71.80% | 1.09% |
APG | -0.01% | $6.48B | +17.62% | 0.00% |
HALO | -0.02% | $7.04B | +58.52% | 0.00% |
BSX | -0.02% | $144.69B | +60.80% | 0.00% |
ROG | 0.02% | $1.79B | -16.00% | 0.00% |
SPT | -0.03% | $1.85B | -46.28% | 0.00% |
WSBC | 0.03% | $2.12B | +9.80% | 4.56% |
REGN | -0.04% | $76.18B | -25.46% | 0.00% |
AGCO | -0.04% | $7.46B | -11.70% | 1.15% |
TEVA | 0.04% | $24.60B | +97.27% | 0.00% |
SSL | 0.05% | $3.14B | -41.69% | 1.93% |
CRVL | 0.05% | $5.59B | +41.24% | 0.00% |
WAFD | 0.05% | $2.52B | +6.97% | 3.49% |
DBRG | -0.05% | $1.95B | -37.39% | 0.35% |
HAIN | 0.05% | $424.81M | -55.94% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KRRO | 33.45% | $346.44M | -9.85% | 0.00% |
PINE | 27.47% | $242.93M | +9.10% | 6.53% |
VSEC | 25.81% | $2.08B | +74.55% | 0.39% |
SEAT | 24.96% | $637.87M | -16.38% | 0.00% |
PSQH | 24.60% | $195.63M | -11.07% | 0.00% |
TLK | 23.01% | $16.04B | -36.51% | 6.74% |
LEU | 22.41% | $1.21B | +34.68% | 0.00% |
GTLB | 22.36% | $10.42B | -1.38% | 0.00% |
MP | 22.33% | $3.46B | +33.48% | 0.00% |
VYGR | 21.70% | $276.41M | -30.49% | 0.00% |
OKLO | 21.04% | $2.96B | +127.83% | 0.00% |
NCNO | 20.86% | $3.81B | +1.64% | 0.00% |
RLAY | 20.76% | $723.09M | -58.02% | 0.00% |
KYMR | 20.75% | $2.61B | +48.13% | 0.00% |
XNCR | 20.68% | $1.40B | +1.83% | 0.00% |
REXR | 20.24% | $8.84B | -26.08% | 4.19% |
PKE | 19.93% | $279.86M | -0.21% | 3.55% |
FCPT | 19.69% | $2.68B | +15.40% | 4.99% |
GCMG | 19.61% | $582.79M | +49.71% | 3.36% |
UUUU | 19.49% | $996.78M | -33.29% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MEAR | -0.07% | $777.56M | 0.25% |
IYK | 0.13% | $1.22B | 0.4% |
SOXX | 0.14% | $14.41B | 0.35% |
HIGH | 0.16% | $248.91M | 0.52% |
COMT | -0.18% | $714.17M | 0.48% |
PXJ | -0.21% | $40.24M | 0.66% |
FTXL | 0.23% | $349.65M | 0.6% |
VDC | -0.26% | $6.87B | 0.1% |
CLSE | -0.28% | $249.35M | 1.55% |
TBLL | 0.33% | $1.98B | 0.08% |
CSHI | -0.34% | $522.07M | 0.38% |
SOXQ | 0.35% | $472.76M | 0.19% |
XLP | -0.36% | $15.94B | 0.09% |
IGE | 0.37% | $655.03M | 0.41% |
XYLD | 0.40% | $3.10B | 0.6% |
FSTA | -0.41% | $1.18B | 0.084% |
KBE | 0.43% | $2.42B | 0.35% |
KRE | -0.46% | $4.95B | 0.35% |
SPMO | 0.48% | $4.11B | 0.13% |
MLPX | 0.56% | $2.76B | 0.45% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FLOT | -22.52% | $7.89B | 0.15% |
BOXX | -11.82% | $4.76B | 0.1949% |
FLTR | -7.82% | $1.98B | 0.14% |
BILZ | -7.64% | $616.99M | 0.14% |
AGZD | -7.15% | $148.43M | 0.23% |
KRBN | -7.09% | $198.93M | 0.85% |
XBIL | -6.29% | $643.80M | 0.15% |
CANE | -5.98% | $11.58M | 0.29% |
TPMN | -5.50% | $41.98M | 0.65% |
MINT | -5.37% | $12.10B | 0.35% |
CTA | -5.11% | $553.08M | 0.76% |
RSPG | -5.05% | $555.79M | 0.4% |
DBA | -4.93% | $817.28M | 0.93% |
IYE | -4.55% | $1.36B | 0.39% |
UNG | -4.53% | $852.04M | 1.06% |
DRLL | -4.41% | $323.08M | 0.41% |
IEO | -4.39% | $621.50M | 0.4% |
FLMX | -4.20% | $72.71M | 0.19% |
XLE | -4.15% | $35.04B | 0.09% |
FTXN | -4.01% | $168.31M | 0.6% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
REMX | 17.68% | $241.92M | 0.56% |
HYSA | 16.83% | $30.05M | 0.55% |
AGGH | 16.73% | $258.23M | 0.29% |
ULST | 16.34% | $549.72M | 0.2% |
BSJQ | 16.16% | $940.00M | 0.42% |
PID | 16.15% | $810.05M | 0.53% |
IZRL | 16.12% | $103.22M | 0.49% |
BATT | 15.64% | $65.99M | 0.59% |
BSJP | 15.53% | $1.01B | 0.42% |
EPHE | 15.15% | $92.11M | 0.59% |
BETZ | 15.14% | $71.78M | 0.75% |
LDSF | 15.01% | $126.19M | 0.75% |
PTH | 14.92% | $116.47M | 0.6% |
PINK | 14.86% | $140.10M | 0.5% |
DFSD | 14.83% | $3.90B | 0.16% |
HYDB | 14.75% | $1.19B | 0.35% |
IBD | 14.33% | $337.54M | 0.44% |
PBDC | 14.32% | $157.26M | 13.94% |
URA | 14.27% | $3.36B | 0.69% |
BIZD | 14.26% | $1.40B | 13.33% |